• Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer 

      Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, A.; Nikolaienko, Oleksii; Vintermyr, Olav Karsten; Lillestøl, Reidun Kristine; Minsaas, Laura; Leirvaag, Beryl; Iversen, Gjertrud Titlestad; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Aase, Hildegunn Siv; Aas, Turid; Gudlaugsson, Einar; Llop-Guevara, Alba; Serra, Violeta; Janssen, Emiel; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2023)
      Purpose Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to ...
    • Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1) 

      Ohnstad, Hege Oma; Blix, Egil Støre; Akslen, Lars Andreas; Gilje, Bjørnar; Raj, Sunil Xavier; Skjerven, Helle; Borgen, Elin; Janssen, Emiel; Mortensen, Elin Synnøve; Brekke, Marianne B.; Falk, Ragnhild Sørum; Schlichting, Ellen; Boge, Beate; Songe-Møller, Silje; Olsson, Pernilla Marie A.; Heie, Anette; Mannsåker, Bård; Vestlid, Magdalena Aas; Kursetgjerde, Torgunn; Gravdehaug, Berit; Suhrke, Pål; Sánchez, E.; Bublevic, J.; Røe, Oluf Dimitri; Geitvik, Gry; Halset, Eline Holli; Rypdal, Maria Christine; Langerød, Anita; Lømo, Jon; Garred, Øystein; Porojnicu, Alina Carmen; Engebraaten, O.; Geisler, Jürgen; Lyngra, Marianne; Hansen, M. H.; Søiland, Håvard; Nakken, T.; Asphaug, Lars; Kristensen, Vessela N.; Sørlie, Therese; Sørlie, T.; Nygård, Jan Franz; Kiserud, Cecilie E.; Reinertsen, Kristin Valborg; Russnes, Hege Elisabeth Giercksky; Naume, Bjørn (Peer reviewed; Journal article, 2024)
      Background EMIT-1 is a national, observational, single-arm trial designed to assess the value of the Prosigna, Prediction Analysis of Microarray using the 50 gene classifier (PAM50)/Risk of Recurrence (ROR), test as a ...
    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; CAMERON, MARTE; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn (Peer reviewed; Journal article, 2022)
      Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed ...
    • Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen 

      Helland, Thomas; Naume, Bjørn; Hustad, Steinar; Bifulco, Ersilia; Kvaløy, Jan Terje; Sætersdal, Anna Barbro; Synnestvedt, Marit; Lende, Tone Hoel; Gilje, Bjørnar; Mjaaland, Ingvil; Weyde, Kjetil; Blix, Egil Støre; Wiedswang, Gro; Borgen, Elin; Hertz, Daniel Louis; Janssen, Emiel; Mellgren, Gunnar; Søiland, Håvard (Peer reviewed; Journal article, 2020)
      Low steady‐state levels of active tamoxifen metabolites have been associated with inferior treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast cancer (BC) patients receiving adjuvant ...
    • Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development 

      Nikolaienko, Oleksii; Eikesdal, Hans Petter; Berge, Elisabet Ognedal; Gilje, Bjørnar; Lundgren, Steinar; Blix, Egil Støre; Espelid, Helge; Geisler, Jürgen; Geisler, Stephanie; Janssen, Emiel; Yndestad, Synnøve; Minsaas, Laura; Leirvaag, Beryl; Lillestøl, Reidun Kristine; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2023)
      Background Normal cell BRCA1 epimutations have been associated with increased risk of triple-negative breast cancer (TNBC). However, the fraction of TNBCs that may have BRCA1 epimutations as their underlying cause is ...